Log in

NASDAQ:ABMDABIOMED Stock Price, Forecast & News

$263.84
+8.62 (+3.38 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$255.43
Now: $263.84
$266.35
50-Day Range
$184.92
MA: $231.97
$263.84
52-Week Range
$119.01
Now: $263.84
$285.77
Volume518,874 shs
Average Volume448,165 shs
Market Capitalization$11.88 billion
P/E Ratio59.69
Dividend YieldN/A
Beta0.94
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Read More
ABIOMED logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$840.88 million
Cash Flow$5.27 per share
Book Value$23.64 per share

Profitability

Net Income$203.01 million

Miscellaneous

Employees1,536
Market Cap$11.88 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

How has ABIOMED's stock been impacted by COVID-19 (Coronavirus)?

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABMD stock has increased by 74.6% and is now trading at $263.84. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ABIOMED?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for ABIOMED.

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) released its earnings results on Thursday, April, 30th. The medical equipment provider reported $0.70 EPS for the quarter, missing the Zacks' consensus estimate of $0.96 by $0.26. The medical equipment provider had revenue of $206.66 million for the quarter, compared to analyst estimates of $209.58 million. ABIOMED had a net margin of 24.14% and a return on equity of 18.51%. The company's quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the business earned $1.60 EPS. View ABIOMED's earnings history.

What price target have analysts set for ABMD?

8 equities research analysts have issued 1 year price targets for ABIOMED's shares. Their forecasts range from $152.00 to $240.00. On average, they anticipate ABIOMED's share price to reach $193.00 in the next twelve months. This suggests that the stock has a possible downside of 26.8%. View analysts' price targets for ABIOMED.

Has ABIOMED been receiving favorable news coverage?

News stories about ABMD stock have trended negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ABIOMED earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about ABIOMED.

Are investors shorting ABIOMED?

ABIOMED saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 2,360,000 shares, a decrease of 13.6% from the June 15th total of 2,730,000 shares. Based on an average daily trading volume, of 559,700 shares, the days-to-cover ratio is currently 4.2 days. Currently, 5.4% of the company's shares are sold short. View ABIOMED's Current Options Chain.

Who are some of ABIOMED's key competitors?

What other stocks do shareholders of ABIOMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE).

Who are ABIOMED's key executives?

ABIOMED's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
  • Dr. David M. Weber, Chief Operating Officer (Age 58)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
  • Mr. William J. Bolt, Exec. Officer (Age 67)
  • Mr. Ian McLeod, VP & Corp. Controller

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $263.84.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $11.88 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

What is ABIOMED's official website?

The official website for ABIOMED is www.abiomed.com.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.